Posted on Leave a comment

Rheumatoid Arthritis Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

Rheumatoid Arthritis Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight 2024” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

  • DelveInsight’s Rheumatoid Arthritis pipeline report depicts a robust space with 95+ active players working to develop 100+ pipeline therapies for Rheumatoid Arthritis treatment.
  • The leading Rheumatoid Arthritis Companies working in the market include Yuyu Pharma, Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc., PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences, Inc., ICMBIO, and others.
  • Promising Rheumatoid Arthritis therapies in the various stages of development include BMS-582949, Imvotamab, etanercept, R-2487, and others.
  • May 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).
  • April 2024:- Pfizer- Characteristics and 6-month Outcomes Among Real-World Rheumatoid Arthritis Patients Initiating Inflectra. This is a retrospective observational study looking at the characteristics and outcomes of participants taking Inflectra using the CorEvitas Rheumatoid Arthritis Registry.

 

Request a sample and discover the recent advances in Rheumatoid Arthritis treatment drugs @ Rheumatoid Arthritis Pipeline Outlook Report

 

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease known to adversely impact the joints of the body. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harms the joints.

 

The disorder does not stay constrained to joints of hands and legs. It has the power to influence any part of the body that involves synovial fluid; approximately 30% of the people who suffer from RA experience pain and other remarkable signs and symptoms that do not involve joints, including heart, kidneys, salivary glands, nerve tissues, skin, eyes bone marrow, blood vessels. The exact cause of RA is still not known.

 

Rheumatoid Arthritis Emerging Drugs Profile

  • SM03: SinoMab
  • SHR0302: Jiangsu Hengrui Medicine
  • RC18: RemeGen
  • Zalunfiban: CeleCor Therapeutics
  • ABBV-3373: Abbvie
  • Dazodalibep: Horizon Therapeutics
  • AP1189: Synact Pharma
  • Dekavil: Philogen

 

Find out more about Rheumatoid Arthritis treatment drugs @ Drugs for Rheumatoid Arthritis Treatment

 

Rheumatoid Arthritis Therapeutics Assessment

There are approx. 95+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase I/II include, RHEACELL.

 

DelveInsight’s Rheumatoid Arthritis pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Rheumatoid Arthritis pipeline therapies @ Rheumatoid Arthritis Clinical Trials

 

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Rheumatoid Arthritis Companies

Yuyu Pharma, Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc., PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences, Inc., ICMBIO, and others.

 

Dive deep into rich insights for new drugs for Rheumatoid Arthritis Treatment, visit @ Rheumatoid Arthritis Drugs

 

Scope of the Rheumatoid Arthritis Pipeline Report

  • Coverage- Global
  • Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Rheumatoid Arthritis Companies- Yuyu Pharma, Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc., PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences, Inc., ICMBIO, and others.
  • Rheumatoid Arthritis Therapies- BMS-582949, Imvotamab, etanercept, R-2487, and others.

 

For further information on the Rheumatoid Arthritis Pipeline Therapeutics, reach out @ Rheumatoid Arthritis Treatment Drugs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Rheumatoid Arthritis : Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Rheumatoid Arthritis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SM03: SinoMab
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ABBV-3373: Abbvie
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SVT 6A4710: Servatus Biopharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. SYN060: Synermore Biologics Co., Ltd.
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. CABA-201: Cabaletta Bio
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Rheumatoid Arthritis – Collaborations Assessment- Licensing / Partnering / Funding
  24. Rheumatoid Arthritis – Unmet Needs
  25. Rheumatoid Arthritis – Market Drivers and Barriers
  26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/